

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.*

# **WHO Expert Committee on Biological Standardization**

---

Thirty-second Report

World Health Organization  
Technical Report Series  
673

---



World Health Organization, Geneva 1982

ISBN 92 4 120673 X

© World Health Organization 1982

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

81/5154 – Schüler – 6500

c.3 D


WORLD HEALTH ORGANIZATION  
TECHNICAL REPORT SERIES

No. 673

**WHO EXPERT COMMITTEE ON BIOLOGICAL  
STANDARDIZATION**

**Thirty-second Report**

**CORRIGENDUM**



Page 32, lines 18–23

*Delete:*

The Committee established the histoplasmin as the International Reference Reagent of Histoplasmin and established the serum as the International Reference Reagent of Histoplasmin for H and M Immunodiffusion Test, and the International Reference Reagent of Histoplasmin Antiserum, Rabbit, for H and M Immunodiffusion Test.

*Insert:*

The Committee established the histoplasmin as the International Reference Reagent of Histoplasmin for H and M Immunodiffusion Test, and the serum as the International Reference Reagent of Histoplasmin Antiserum, Rabbit, for H and M Immunodiffusion Test.

*Continued overleaf*

Delete:

	Disc content	Expected range of zone diameters (mm)
<i>Staphylococcus aureus</i> (ATCC 25923)		
sulfamethoxazole/trimethoprim	23.75 mg/1.25 µg	24–32
sulfafurazole	250 g	24–32

Insert:

	Disc content	Expected range of zone diameters (mm)
<i>Staphylococcus aureus</i> (ATCC 25923)		
sulfamethoxazole/trimethoprim	23.75 µg/1.25 µg	24–32
sulfafurazole	250 µg	24–32

# CONTENTS

	Page
General .....	7
The provision of international standards .....	7
The establishment of biological laboratories .....	8
The provision of working standards .....	9
The reconstitution and use of standards .....	10
The assignment of units of activity .....	10
Biological standards for clinical chemistry .....	12
Antibiotic susceptibility tests .....	13
Poliomyelitis vaccine (inactivated) .....	14
Requirements for Rift Valley fever vaccine .....	14
Stability of measles vaccine .....	15
Test for pyrogens .....	15
New biologicals prepared by gene control and other methods .....	16
SUBSTANCES	
<b>Antibiotics</b>	
1. Amikacin .....	16
2. Sisomicin .....	17
3. Tobramycin .....	17
4. Bleomycin A5 .....	18
5. Nystatin .....	18
<b>Antibodies</b>	
6. <i>Clostridium botulinum</i> type B antitoxin .....	18
7. <i>Clostridium welchii</i> (perfringens) types B and D antitoxins .....	19
8. Anti-poliovirus sera types 1, 2 and 3 .....	19
9. Anti-streptolysin O, human .....	20
10. Anti-rubella serum, human .....	20
11. Anti-varicella zoster immunoglobulin, human .....	20
12. Hapatitis A immunoglobulin .....	21
<b>Antigens</b>	
13. Tetanus toxoid, adsorbed .....	21
14. Purified protein derivative (PPD) of mammalian tuberculin .....	22
15. Rabies vaccine .....	22
16. Tetanus toxin .....	23
17. Yellow fever vaccine .....	23
<b>Blood Products and Related Substances</b>	
18. Haemiglobincyanide .....	24
19. Plasmin .....	24
20. Blood coagulation factor VIII in human plasma .....	25
21. Anti-A, anti-B and anti-A,B blood typing serum .....	25

22. Fluorescein isothiocyanate-conjugated sheep anti-human IgG (anti- $\gamma$ -chain) .....	26
23. International reference preparation of calcium, chloride, magnesium, potassium, and sodium in serum .....	26
<b>Endocrinological and Related Substances</b>	
24. Human growth hormone .....	27
25. Follicle-stimulating hormone (FSH), pituitary, human, for immunoassay .....	27
26. Parathyroid hormone, human, for immunoassay .....	28
27. Parathyroid hormone, bovine, for bioassay .....	28
28. Insulin .....	29
29. Thyroid stimulating hormone, human, for immunoassay .....	29
30. Chorionic gonadotrophin, human .....	29
31. Prolactin, human, for immunoassay .....	30
32. Tetracosactide for bioassay .....	30
33. Kininogenases .....	31
<b>Reference Reagents</b>	
34. Adenovirus antisera, equine: types 34, 35 and 36 .....	31
35. Histoplasmin antigen (H and M) and its antiserum, rabbit .....	32
<b>REQUIREMENTS FOR BIOLOGICAL SUBSTANCES</b>	
36. Requirements for pertussis vaccine, single or combined .....	32
37. The dating period of vaccines containing a pertussis component .....	33
38. Requirements for poliomyelitis vaccine (inactivated) .....	33
39. A review of tests on virus vaccines .....	34
40. Requirements for Rift Valley fever vaccine .....	35
41. Requirements for antibiotic susceptibility tests .....	35
42. Stability of measles vaccine .....	36
43. The collection, fractionation, quality control and uses of blood and related products .....	36
Acknowledgements .....	37
<b>ANNEXES</b>	
Annex 1. Requirements for diphtheria toxoid, pertussis vaccine, tetanus toxoid and combined vaccines (Addendum 1981) .....	38
Annex 2. Requirements for poliomyelitis vaccine (inactivated) .....	40
Annex 3. A review of tests on virus vaccines: report of a group of consultants .....	85
Annex 4. Proposed requirements for Rift Valley fever vaccine (inactivated) for human use .....	104
Annex 5. Requirements for antimicrobial susceptibility tests. I. Agar diffusion tests using antimicrobial susceptibility discs .....	144
Annex 6. Requirements for measles vaccine (live) (Addendum, 1981) .....	179
Annex 7. Biological substances: international standards, reference preparations, and reference reagents .....	180

## WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 22–28 September 1981

### Members\*

- Professor S. G. Dzagurov, Director, Tarasevič State Institute for the Standardization and Control of Medical Biological Preparations, Moscow, USSR  
Dr J. W. Lightbown, Head, Division of Antibiotics, National Institute for Biological Standards and Control, London, England (*Chairman*)  
Mr J. Lyng, Vaccine Department, State Serum Institute, Copenhagen, Denmark  
Dr R. Murata, formerly Director-General, National Institute of Health, Tokyo, Japan (*Vice-Chairman*)  
Dr R. Netter, Director-General, National Health Laboratory, Paris, France  
Dr J. Robbins, Director, Division of Bacterial Products, Bureau of Biologics, Food and Drug Administration, Bethesda, MD, USA (*Rapporteur*)  
Mr J. R. Thayer, Head, Antibiotics Section, National Biological Standards Laboratory, Canberra, Australia  
Dr Tsou Pang-Chu, Chief, Division of Bacterial Vaccines, National Institute for the Control of Pharmaceutical and Biological Products, Temple of Heaven, Beijing, China  
Dr W. W. Wright, Senior Scientist, Drug Standards Division, the United States Pharmacopeia and the National Formulary, Rockville, MD, USA

### Secretariat

- Dr J. N. Ashworth, Vice-President, Scientific Affairs, Biological Products, Cutter Laboratories Inc., Berkeley, CA, USA (*Consultant*)  
Dr D. R. Bangham, Head, Division of Hormones, National Institute for Biological Standards and Control, London, England (*Consultant*)  
Mr V. F. Davey, Technical Director, Commonwealth Serum Laboratories, Parkville, Victoria, Australia (*Consultant*)  
Mr W. Duimel, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands (*Consultant*)  
Professor W. Hennessen, Bureau of Applied Immunology, Berne, Switzerland (*Consultant*)  
Dr H. W. Krijnen, Director, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands (*Consultant*)  
Dr F. H. Meskal, Director, Central Laboratory and Research Institute, Addis Ababa, Ethiopia (*Consultant*)  
Dr F. T. Perkins, Chief, Biologicals, WHO, Geneva, Switzerland (*Secretary*)  
Dr J. D. van Ramhorst, Biologicals, WHO, Geneva, Switzerland  
Dr D. P. Thomas, Head, Division of Blood Products, National Institute for Biological Standards and Control, London, England (*Consultant*)

---

\* Unable to attend: Dr Chou Hai-chun, Vice-Director, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China; Professor B. Lunenfeld, Director, Institute of Endocrinology and Chief of Division of Laboratories, The Chaim Sheba Medical Center, Tel-Hashomer, Israel; Professor F. Oberdoerster, Director, State Institute of Serum and Vaccine Testing of the German Democratic Republic, Berlin.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30806](https://www.yunbaogao.cn/report/index/report?reportId=5_30806)

